|Expense Ratio (net)||1.52%|
|Morningstar Risk Rating||★★★★★|
|Last Cap Gain||0.00|
|Inception Date||Dec 27, 2012|
|Average for Category||N/A|
BOSTON, May 09, 2017-- The Eventide Healthcare & Life Sciences Fund was named as a Wall Street Journal“ Category King” for the Health & Biotech Category for the one-year period ending March 31, 2017. The ...
Eventide Funds announced 2016 results for the Eventide Gilead Fund , Eventide Healthcare & Life Sciences Fund , and...
Eventide Asset Management, LLC is proud to announce that Peter Luiso, an attorney and former Vice President in Asset Management Compliance at Fidelity Investments, will join Eventide's growing team as ...